Jazz Pharmaceuticals Plc (JAZZ)

136.62
NASDAQ : Health Technology
Prev Close 138.23
Day Low/High 133.25 / 138.50
52 Wk Low/High 113.52 / 181.46
Avg Volume 477.90K
Exchange NASDAQ
Shares Outstanding 56.64M
Market Cap 7.83B
EPS 7.50
P/E Ratio 17.24
Div & Yield N.A. (N.A)

Latest News

Jazz Pharmaceuticals Receives Schedule IV Designation From DEA For Sunosi™ (solriamfetol)

Jazz Pharmaceuticals Receives Schedule IV Designation From DEA For Sunosi™ (solriamfetol)

Sunosi expected to be commercially available in the U.S. July 2019

Jazz Pharmaceuticals Appoints Dr. Robert Iannone As Executive Vice President, Research And Development

Jazz Pharmaceuticals Appoints Dr. Robert Iannone As Executive Vice President, Research And Development

DUBLIN, June 3, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the appointment of Robert Iannone, M.

Jazz Pharmaceuticals To Present New Data At Upcoming ASCO Annual Meeting And EHA Congress

Jazz Pharmaceuticals To Present New Data At Upcoming ASCO Annual Meeting And EHA Congress

Data to be presented underscore commitment to developing life-changing medicines in hematology/oncology for people with limited or no treatment options

Jazz Pharmaceuticals Data To Showcase Ongoing Sleep Medicine Research At SLEEP 2019

Jazz Pharmaceuticals Data To Showcase Ongoing Sleep Medicine Research At SLEEP 2019

Fourteen abstracts highlight Jazz's breadth in sleep medicine research and commitment to developing treatment options for people living with debilitating sleep disorders

Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

Total Revenues Increased 14% to $508 Million

Jazz Pharmaceuticals Announces Participation In Two Upcoming Investor Conferences

Jazz Pharmaceuticals Announces Participation In Two Upcoming Investor Conferences

DUBLIN, May 6, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentations at two upcoming investor conferences.

Jazz Pharmaceuticals To Report 2019 First Quarter Financial Results On May 7, 2019

Jazz Pharmaceuticals To Report 2019 First Quarter Financial Results On May 7, 2019

DUBLIN, April 23, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2019 first quarter financial results on Tuesday, May 7, 2019, after the close of the financial markets.

Jazz Pharmaceuticals Announces Positive Top-line Results From Phase 3 Study Of JZP-258 In Adult Narcolepsy Patients With Cataplexy And Excessive Daytime Sleepiness

Jazz Pharmaceuticals Announces Positive Top-line Results From Phase 3 Study Of JZP-258 In Adult Narcolepsy Patients With Cataplexy And Excessive Daytime Sleepiness

JZP-258 achieves primary and key secondary endpoints demonstrating highly statistically significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo

Jazz Pharmaceuticals Announces U.S. FDA Approval Of Sunosi™ (solriamfetol) For Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

Jazz Pharmaceuticals Announces U.S. FDA Approval Of Sunosi™ (solriamfetol) For Excessive Daytime Sleepiness Associated With Narcolepsy Or Obstructive Sleep Apnea

Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor approved by the FDA to improve wakefulness in adults living with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea

Jazz Pharmaceuticals To Present At The Cowen And Company 39th Annual Healthcare Conference

Jazz Pharmaceuticals To Present At The Cowen And Company 39th Annual Healthcare Conference

DUBLIN, March 5, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will be webcasting its corporate presentation at the Cowen and Company 39th Annual Healthcare Conference in Boston, MA.

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2018 Financial Results

Total Revenues Increased 17% to $1.9 Billion in 2018

2 Stocks You Really Should Consider Shorting This Week

2 Stocks You Really Should Consider Shorting This Week

These 'Bearish Bets' are showing both technical and quantitative deterioration.

A Biotech Firm, an Airline and Other Stocks That Look Good Short

JAZZ, CTL, NLY, NUS and CPA all recently were downgraded by TheStreet's Quant Ratings.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ABC, ALKS, AUY, BY, CCS, CXO, DVN, HGV, IESC, KRG, OMF, VRNT Downgrades: ARR, CTG, JAZZ, PTN, ROX Initiations: LBRT, NINE Read on to get TheStreet Quant Ratings' detailed report:

Jazz Pharmaceuticals Announces Appointment Of Anne O'Riordan To Its Board Of Directors

Jazz Pharmaceuticals Announces Appointment Of Anne O'Riordan To Its Board Of Directors

DUBLIN, Feb. 14, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Anne O'Riordan, Senior Managing Director, Life Sciences of Accenture, was appointed to its Board of Directors, effective February 14, 2019.

Jazz Pharmaceuticals To Report 2018 Fourth Quarter And Full Year Financial Results On February 26, 2019

Jazz Pharmaceuticals To Report 2018 Fourth Quarter And Full Year Financial Results On February 26, 2019

DUBLIN, Feb. 12, 2019 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2018 fourth quarter and full year financial results on Tuesday, February 26, 2019, after the close of the financial markets.

New Year's Investing Resolutions

New Year's Investing Resolutions

The market's day-to-day extreme volatility tested even the most seasoned investors. Adhering to portfolio principles can help.

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

Why Thousands Will Attend ASH Hematology Conference in Atlanta This Weekend

The FDA approved 11 different hematological treatments this year after approving 11 in the previous two years combined.

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

Acorda Shares Down on FDA's 'Refusal to File' Letter - Biotech Movers

The firm received a "refusal to file letter" from the FDA regarding the new drug application for Inbrija, a potential treatment for Parkinson's disease.

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals And ImmunoGen, Inc. Announce A Strategic Collaboration And Option Agreement To Develop And Commercialize Antibody-Drug Conjugate Products

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights...

Biotech Movers: Jazz Shares Lower Amid Notes Offering

Biotech Movers: Jazz Shares Lower Amid Notes Offering

The Dublin firm announced an offering of $500 million of exchangeable senior notes due 2024.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Trevena, Synergy Lead Biotech Movers

Trevena, Synergy Lead Biotech Movers

Positive phase three data was a boon for Trevena, but Synergy's "Poop Troop" put pressure on its stock.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACSF, CAA, JAZZ, LFL, MTH, SUM, WYNN Downgrades: REV, TROW, WAGE Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

ChemoCentryx, Jazz Pharmaceuticals, Ionis Pharmaceuticals and Zogenix were among the biotech stock movers in premarket trading Friday.

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

How Investors Can Play the Trump Card: Cramer's 'Mad Money' Recap (Monday 1/23/17)

Jim Cramer looks for domestic stocks he thinks will benefit from lower taxes and deregulation in the Trump era.

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Fitbit Is Out, Xilinx Is In: 'Mad Money' Lightning Round

Jim Cramer says the future doesn't look healthy for Fitbit, but he's bullish on Xilinx and T-Mobile.

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

Jazz Pharma, CoLucid Spike Premarket, Plus Other Biotech Movers

CoLucid Pharmaceuticals saw shares boost 32% ahead of the market open Wednesday.

TheStreet Quant Rating: C+ (Hold)